RECENT PLACEMENT

Occam Places Bill Brondyk as CSO at Invetx

Occam Places Bill Brondyk as CSO at Invetx

Invetx, an Anterra Capital investment, is building the world’s premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. In 2020, the company raised a $15M series A to advance Invetx’s pipeline of veterinary biologic drugs leveraging breakthroughs in human biopharma. Partnerships with AbCellera and WuXi Biologics followed shortly after. And in 2022, the company closed a $60M series B from F-Prime, Novo and Casdin.

But before all that, in September of 2019, Occam recruited Bill Brondyke to be the company's first CSO. Brondyke is seasoned drug hunter with 20+ years of experience in developing protein therapeutics for oncology indications, immune-mediated diseases, infectious diseases, rare diseases and reproductive health and contraception.

‍

Recent Placements

  1. Bastiano Sanna as CEO of Semma
  2. Bill Brondyk as CSO at Invetx
  3. Aron Feingold as VP of Investor Relations & Corporate Communications at Geron
  4. Brian Goldman as Chief Computation Officer at ZebiAI
  5. Ann Taylor as Board Member at Comanche Biopharma
About Occam Global

Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.